Patent
Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
| العنوان: | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity |
|---|---|
| Patent Number: | 7,868,005 |
| تاريخ النشر: | January 11, 2011 |
| Appl. No: | 11/354138 |
| Application Filed: | February 14, 2006 |
| مستخلص: | The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: [chemical expression included] and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1. |
| Inventors: | Rosenblum, Stuart B. (West Orange, NJ, US); Kim, Seong Heon (Livingston, NJ, US); Zeng, Qingbei (Edison, NJ, US); Wong, Michael K. C. (North Brunswick, NJ, US); Anilkumar, Gopinadhan N. (Edison, NJ, US); Jiang, Yueheng (Whitehouse Station, NJ, US); Yu, Wensheng (Edison, NJ, US); Kozlowski, Joseph A. (Princeton, NJ, US); Shih, Neng-Yang (Warren, NJ, US); Shankar, Bandarpalle B. (Branchburg, NJ, US); McGuinness, Brian F. (Plainsboro, NJ, US); Dong, Guizhen (Dayton, NJ, US); Zawacki, Lisa Guise (Yardley, PA, US); Hobbs, Douglas W. (Yardley, PA, US); Baldwin, John J. (Gwynedd Valley, PA, US); Shao, Yuefei (Princeton, NJ, US) |
| Assignees: | Schering Corporation (Kenilworth, NJ, US) |
| Claim: | 1. A compound having the structure shown in Formula 1: [chemical expression included] or a pharmaceutically acceptable salt thereof wherein: X is N, O, alkyl, or heteroaryl; ring D is a phenyl ring unsubstituted or optionally substituted with independently selected R 20 moieties as stated below; R 1 and R 2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkyl, alkoxy, alkenyl, carbonyl, cycloalkyl, alkyl-cycloalkyl-, cycloalkenyl, alkylaryl, arylalkyl, aryl, amino, alkylamino, amidinyl, carboxamido, cyano, hydroxyl, urea, —N≡CH, ═NCN, (CH 2) q CH, —(CH 2) q OR 31 , —(CH 2) q CF 3 , —(CH 2) q NH 2 , —(CH 2) q NHR 31 , —(CH 2) q N(R 31) 2 , —(CH 2) q -amidinyl, cyclopropylhydroxy, cyclobutylhydroxy, cyclopentylhydroxy, —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , —C(═S)N(H)alkyl, —N(H)—S(O) 2 -alkyl, —N(H)C(═O)N(H)-alkyl, —S(O) 2 alkyl, —S(O) 2 N(H)alkyl, —S(O) 2 N(alkyl) 2 , —S(O) 2 aryl, —C(═S)N(H)cycloalkyl, —C(═O)N(H)NH 2 , —C(═O))alkyl, —CH 2 CH 2 Ophenyl, —CH 2 CH(OCH 2 CH 3) 2 , —C(═O)NHcyclopropyl, —C(═O)N(H)CH 2 CF 3 , —S(O) 2 CH 2 CF 3 , —S(O) 2 CF 3 , -heteroaryl, heterocyclyl, heterocyclenyl, difluorophenyl, aminooxadiazolyl, fluorophenylmethylene, trifluoromethylphenylmethylene, cyanophenylmethylene, difluorophenylmethylene, bromophenylmethylene, chlorophenylmethylene, bromochlorophenylmethylene, fluorochlorophenylmethylene, dichlorophenylmethylene, methoxylphenylmethylene, —CH 2 -cyclopropyl, cyclohexylmethylene, 5-methyl-isoxazolyl, chloropyridyl, pyridylmethylene, [chemical expression included] or alternatively when X is N, the N taken together with the R 1 and R 2 forms a heterocycyl, heteroaryl or —N═C(NH 2) 2 ; R 3 is selected from the group consisting of H, alkyl, haloalkyl, halogen, —N(R 30) 2 , and —OR 30 ; R 6 is selected from the group consisting of H and —N(R 30) 2 ; R 7 and R 8 taken together are ═O; the R 10 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, —(CH 2) q OH, —(CH 2) q OR 31 , and —OR 30 ; the R 11 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, carboxamide, and —OR 30 ; R 12 is selected from the group consisting of H and alkyl; the R 20 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, cyano, cycloalkyl, cycloalkenyl, formyl, guanidinyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl, haloalkoxy, hydroxamate, nitro, trifluoromethyl, trifluoromethoxy, —(CH 2) q OH, —(CH 2) q OR 31 , —(CH 2) q NH 2 , —(CH 2) q NHR 31 , —(CH 2) q N(R 31) 2 , —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , -alkynylC(R 31) 2 OR 31 , —C(═O)R 30 , —C(═O)N(R 30) 2 , —C(═NR 30)NHR 30 , —C(═NOH)N(R 30) 2 , —C(═NOR 31)N(R 30) 2 , —C(═O)OR 30 , —N(R 30) 2 , —N(R 30)C(═O)R 31 , —NHC(═O)N(R 30) 2 , —N(R 30)C(═O)OR 31 , —N(R 30)C(═NCN)N(R 30) 2 , —N(R 30)C(═O)N(R 30)SO 2 (R 31), —N(R 30)C(═O)N(R 30) 2 , —N(R 30)SO 2 (R 31), —N(R 30)S(O) 2 N(R 30) 2 , —OR 30 , —OC(═O)N(R 30) 2 , —SR 30 , —SO 2 N(R 30) 2 , —SO 2 (R 31), —OSO 2 (R 31), —O(CH 2) q SO 2 R 31 , and —OSi(R 30) 3 ; or alternatively two R 20 moieties are linked together to form a five or six membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring wherein said five or six membered aryl, cycloalkyl, heterocyclyl, heterocyclenyl, or heteroaryl ring is fused to ring D and the fused ring is optionally substituted with 0-4 R 21 moieties; the R 21 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkenyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylthiocarboxy, alkylheteroaryl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkenyl, aralkoxy, aralkoxycarbonyl, aralkylthio, aryl, aroyl, aryloxy, carboxamido, cyano, cycloalkyl, cycloalkenyl, formyl, guanidinyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, heterocyclenyl, hydroxyalkyl, hydroxamate, nitro, trifluoromethoxy, —(CH 2) q OH, —(CH 2) q OR 31 , —(CH 2) q NH 2 , —(CH 2) q NHR 31 , —(CH 2) q N(R 31) 2 , —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , -alkynylC(R 31) 2 OR 31 , —C(═O)R 30 , —C(═O)N(R 30) 2 , —C(═NR 30)NHR 30 , —C(═NOH)N(R 30) 2 , —C(═NOR 31)N(R 30) 2 , —C(═O)OR 30 , —N(R 30) 2 , —N(R 30)C(═O)R 31 , —NHC(═O)N(R 30) 2 , —N(R 30)C(═O)OR 31 , —N(R 30)C(═NCN)N(R 30) 2 , —N(R 30)C(═O)N(R 30)SO 2 (R 31), —N(R 30)C(═O)N(R 30) 2 , —N(R 30)SO 2 (R 31), —N(R 30)S(O) 2 N(R 30) 2 , —OR 30 , —OC(═O)N(R 30) 2 , —SR 30 , —SO 2 N(R 30) 2 , —SO 2 (R 31), —OSO 2 (R 31), and —OSi(R 30) 3 ; Y is selected from the group consisting of —(CR 13 R 13) r —, —(CHR 13) r O—, —C(═O)—, —C(═NR 30)—, —(C(H)(heteroaryl))—, —(CHR 13) r C(═O)— and —(CHR 13) r N(H)C(═O)—; the R 13 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, —CO 2 H, —C(═O)OR 31 , —C(═O)N(R 30) 2 , —(CHR 30) q OH, —(CHR 30) q OR 31 , —(CHR 30) q NH 2 , and —(CH 2) q NHSO 2 R 31 ; the R 30 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, aralkyl, cycloalkyl, —(CH 2) q OH, —(CH 2) q Oalkyl, —(CH 2) q NH 2 , —(CH 2) q NHalkyl, —(CH 2) q N(alkyl) 2 , —(CH 2) q NHaralkyl, —(CH 2) q C(═O)NHalkyl, —(CH 2) q C(═O)N(alkyl) 2 , —(CH 2) q C(═O)NHaralkyl, —(CH 2) q SO 2 alkyl, and —(CH 2) q SO 2 NHalkyl; the R 31 moieties can be the same or different, each being independently selected from the group consisting of alkyl, aralkyl, cycloalkyl, —(CH 2) q OH, —(CH 2) q Oalkyl, —(CH 2) q NH 2 , —(CH 2) q NHalkyl, —(CH 2) q N(alkyl) 2 , —(CH 2) q NHaralkyl, —(CH 2) q C(═O)NHalkyl, —(CH 2) q C(═O)N(alkyl) 2 , —(CH 2) q C(═O)NHaralkyl, —(CH 2) q SO 2 alkyl, and —(CH 2) q SO 2 NHalkyl; m is 0 to 4; n is 0 to 4; p is 0 to 5; each q can be the same or different, each being independently selected from 1 to 5; and r is 1 to 4; with the proviso that there are no two adjacent double bonds in any ring, and that when a nitrogen is substituted by two alkyl groups, said two alkyl groups may be optionally joined to each other to form a ring. |
| Claim: | 2. The compound according to claim 1 , wherein R 1 and R 2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkyl, aryl, amino, alkoxy, hydroxy, cycloalkyl, alkyl-cycloalkyl-, cycloalkenyl, arylalkyl, amidinyl, carboxamido, heteroaryl, heterocyclyl, heterocyclenyl, urea, —S(O) 2 alkyl, —S(O) 2 N(H)alkyl, —S(O) 2 N(alkyl) 2 , and —C(═S)N(H)cycloalkyl. |
| Claim: | 3. The compound according to claim 1 , wherein R 1 and R 2 are independently absent or present, and if present each is independently selected from the group consisting of H, alkylaryl, alkyl-cycloalkyl-, aryl, heteroaryl, —(CH 2) q CF 3 , —(CH 2) q OH, —(CH 2) q OR 31 , —(CH 2) q NH 2 , —(CH 2) q NHR 31 , —(CH 2) q N(R 31) 2 , —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , —(CH 2) q -amidinyl, cyclopropyl, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy; and q is an integer from 1 to 5. |
| Claim: | 4. The compound according to claim 1 , wherein R 1 and R 2 are independently absent or present, and if present each is independently selected from the group consisting of H, —CH 3 , fluorophenylmethylene, trifluoromethylphenylmethylene, indanyl, cyanophenylmethylene, difluorophenylmethylene, bromophenylmethylene, chlorophenylmethylene, —CH 2 CH 2 Ophenyl, cyclopentyl, bromochlorophenylmethylene, fluorochlorophenylmethylene, dichlorophenylmethylene, phenylmethylene, —(CH 2) 3 phenyl, —CH 2 CF 3 , methoxylphenylmethylene, —CH(CH 3) 2 , —C 2 H 5 , —CH 2 -cyclopropyl, —(CH 2) 2 CH 3 , cyclohexylmethylene, cyclohexyl, —CH 2 CH 2 SO 2 CH 3 , —CH 2 —CH 2 —NH 2 , —CH 2 CH 2 OCH 3 , cyclopropyl, CH 3 -cyclopropyl, isoxazolyl, —CH 2 CH 2 OH, —CH 2 CH 2 CH 3 , —NH 2 , pyrazolyl, 5-methyl-isoxazolyl, —CH 2 CH(OCH 2 CH 3) 2 , —OCH 3 , —NHC(═O)NH 2 , chloropyridyl, pyridylmethylene, —C(═O)NHcyclopropyl, —C(═O)N(H)C 2 H 5 , —C(═O)N(H)CH 2 CF 3 , —C(═O)N(H)C(CH 3) 3 , —C(═S)N(H)cyclopropyl, —C(═O)NH 2 , —C(═O)N(H)CH 3 , —S(O) 2 CH 3 , —S(O) 2 N(CH 3) 2 , —S(O) 2 CH 2 CH 3 , —C(═O)CH 3 , —S(O) 2 (CH 2) 2 CH 3 , —C(═O)N(H)cyclohexyl, —C(═NH)NH 2 , —C(═O)N(H)NH 2 , —C(═O)N(H)CH(CH 3) 2 , thiazolyl, —C(═O)N(CH 3) 2 , —S(O) 2 CH 2 CF 3 , —S(O) 2 CF 3 , [chemical expression included] [chemical expression included] or when X is N, the N taken together with the R 1 and R 2 to which X is shown attached, forms an aziridine, azetidine, piperidine or [chemical expression included] |
| Claim: | 5. The compound according to claim 1 , wherein R 1 and R 2 are independently absent or present, and if present each is independently selected from the group consisting of H, —CH 3 , —C 2 H 5 , difluorophenylmethylene, cyclopropyl, CH 3 -cyclopropyl-, dichlorophenylmethylene, —CH(CH 3) 2 , cyclohexylmethylene, cyclohexyl, isoxazolyl, oxadiazolyl, aminooxadiazoyl, difluorophenyl, —CH 2 CH 2 OH, —CH 2 CH 2 N(CH 3) 2 , —C(═O)N(H)cyclopropyl, —C(═O)N(H)C 2 H 5 , —C(═O)N(H)CH 2 CF 3 , —C(═O)N(H)CH(CH 3) 2 , —C(═O)N(H)C(CH 3) 3 , —C(═S)N(H)cyclopropyl, —C(═O)NH 2 , —C(═O)N(H)CH 3 , —S(O) 2 CH 3 , —S(O) 2 N(CH 3) 2 , —S(O) 2 CH 2 CH 3 , —C(═O)CH 3 , —S(O) 2 (CH 2) 2 CH 3 , —C(═O)N(H)cyclohexyl, —C(═NH)NH 2 , —C(═O)N(H)NH 2 , thiazolyl, [chemical expression included] |
| Claim: | 6. The compound according to claim 1 , wherein X is selected from the group consisting of N, O, —CH 3 , —CH 2 —, —CH, —CH 2 CH 3 , and [chemical expression included] |
| Claim: | 7. The compound according to claim 1 , wherein R 3 is selected from the group consisting of H, alkyl, halogen, —N(R 30) 2 , —OR 30 and —CF 3 . |
| Claim: | 8. The compound according to claim 1 , wherein R 3 is selected from the group consisting of H, —CH 3 , —CH 2 CH 3 , —F, —Cl, OCH 3 , and CF 3 . |
| Claim: | 9. The compound according to claim 1 , wherein R 6 is selected from the group consisting of H and —NH 2 . |
| Claim: | 10. The compound according to claim 1 , wherein R 10 is selected from the group consisting of —CH 3 , —CH 2 CH 3 and —CH 2 CH 2 CH 3 , and m is 0-2. |
| Claim: | 11. The compound according to claim 1 , wherein R 12 is selected from the group consisting of H, —CH 3 , and —CH 2 CH 3 . |
| Claim: | 12. The compound according to claim 1 , wherein the phenyl ring D is substituted by independently selected 1-4 R 20 moieties. |
| Claim: | 13. The compound according to claim 1 , wherein the R 20 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkylaryl, alkynyl, alkoxy, alkylamino, alkylheteroaryl, alkylsulfinyl, alkoxycarbonyl, aminoalkyl, amidinyl, aralkyl, aralkoxy, aryl, aryloxy, cyano, cycloalkyl, cycloalkenyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxyalkyl, trifluoromethyl, trifluoromethoxy, —(CH 2) q OR 31 , —(CH 2) q NHR 31 , —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , -alkynylC(R 31) 2 R 31 , —C(═O)R 30 , —C(═O)N(R 30) 2 , —O(═O)OR 30 , —N(R 30) 2 , —N(R 30)C(═O)R 31 , —NHC(═O)N(R 30) 2 , —N(R 30)C(═O)OR 31 , —N(R 30)C(═NCN)N(R 30) 2 , —N(R 30)C(═O)N(R 30) 2 , —N(R 30)SO 2 (R 31), —N(R 30)SO 2 N(R 30) 2 , —OR 30 , —OC(═O)N(R 30) 2 , —SR 30 , —SO 2 N(R 30) 2 , —SO 2 (R 31), —OSO 2 (R 31), —O(CH 2) q SO 2 R 31 , and —OSi(R 30) 3 . |
| Claim: | 14. The compound according to claim 1 , wherein the R 20 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkoxy, amino, halogen, CN, CH 3 , CF 3 , OCH 3 , OCF 3 , —(CH 2) q OR 31 , —(CH 2) q NHR 31 , —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , -alkynylC(R 31) 2 R 31 , —C(═O)R 30 , —C(═O)OR 30 , —N(R 30) 2 , —N(R 30)C(═O)R 31 , —NHC(═O)N(R 30) 2 , —N(R 30)C(═O)OR 31 , —N(R 30)C(═NCN)N(R 30) 2 , —N(R 30)C(═O)N(R 30) 2 , —OR 30 , —OC(═O)N(R 30) 2 , —O(CH 2) q SO 2 R 31 and —OSO 2 (R 31). |
| Claim: | 15. The compound according to claim 1 , wherein two R 20 moieties are linked together to form a five or six membered aryl, cycloalkyl, heterocyclenyl, heterocyclyl or heteroaryl ring wherein said five or six membered aryl, cycloalkyl, heterocyclenyl, heterocyclyl, and heteroaryl ring is fused to ring D and the fused ring is optionally substituted with 0 to 4 R 21 moieties. |
| Claim: | 16. The compound according to claim 1 , wherein the R 20 moieties can be the same or different, each being independently selected from the group consisting of H, —CN, —CH 3 , —CF 3 , —CH 2 OH, —CO 2 H, —CO 2 CH 3 , —NH 2 , —NHCH 3 , —OCF 3 , —OH, F, Cl, Br, —C(═NOH)NH 2 , —OCH 2 CH 2 S(O 2)CH 3 , —C(═O)NH 2 , [chemical expression included] |
| Claim: | 17. The compound according to claim 1 , wherein Y is selected from the group consisting of: —(CHR 13) r —, —(CR 13 R 13) r —, —C(═O)— and —CHR 13 C(═O)—. |
| Claim: | 18. The compound according to claim 1 , wherein Y is selected from the group consisting of: —CH 2 —, —CH(CH 3)—, —CH(CH 2 OH)—, —C(═O)— and —CH(CO 2 alkyl)-. |
| Claim: | 19. The compound according to claim 1 , wherein m is 0-3. |
| Claim: | 20. The compound according to claim 1 , wherein n is 0-2. |
| Claim: | 21. The compound according to claim 1 , wherein q is 1, 2 or 3. |
| Claim: | 22. The compound according to claim 1 , wherein r is 1 or 2. |
| Claim: | 23. The compound according to claim 1 , wherein X is N; R 1 and R 2 are independently selected from the group consisting of H, alkylaryl, aryl, heteroaryl, —(CH 2) q CF 3 , —(CH 2) q OH, —(CH 2) q OR 31 , —(CH 2) q NH 2 , —(CH 2) q NHR 31 , —(CH 2) q —N(R 31) 2 , —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , —(CH 2) q -amidinyl, cyclopropyl, alkyl-cyclopropyl-, cyclopropylhydroxyl, cyclobutyl, cyclobutylhydroxy, cyclopentyl, and cyclopentylhydroxy; R 3 is selected from the group consisting of H, alkyl, haloalkyl, halogen, —N(R 30) 2 , —OR 30 and —CF 3 ; R 6 is selected from the group consisting of H and —N(R 30); R 7 and R 8 taken together are ═O; R 10 is selected from the group consisting of H and alkyl; R 11 is H; R 12 is selected from the group consisting of H and alkyl; the R 20 moieties can be the same or different, each being independently selected from the group consisting of H, alkyl, alkoxy, amino, halogen, CN, CH 3 , CF 3 , OCH 3 , OCF 3 , —(CH 2) q OR 31 , —(CH 2) q NHR 31 , —(CH 2) q C(═O)NHR 31 , —(CH 2) q SO 2 R 31 , —(CH 2) q NHSO 2 R 31 , —(CH 2) q SO 2 NHR 31 , -alkynylC(R 31) 2 OR 31 , —C(═O)R 30 , —C(═O)OR 30 , —N(R 30) 2 , —N(R 30)C(═O)R 31 , —NHC(═O)N(R 30) 2 , —N(R 30)C(═O)OR 31 , —N(R 30)C(═NCN)N(R 30) 2 , —N(R 30)C(═O)N(R 30) 2 , —OR 30 , —OC(═O)N(R 30) 2 , [chemical expression included] Y is selected from the group consisting of: —CH 2 —, —CH(CH 2 OH)—, —C(═O)— and —CH(CO 2 alkyl)-; m is 0-2; n is 0-2; and q is 1 or 2. |
| Claim: | 24. The compound according to claim 1 , represented by the following structural Formula: [chemical expression included] or a pharmaceutically acceptable salt thereof, wherein the various terms are as defined in claim 1 . |
| Claim: | 25. A compound selected from the group consisting of: [table included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 26. The compound according to claim 25 , selected from the group consisting of: [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 27. A compound of Formula 7, Formula 8, Formula 9, Formula 10, Formula 11, Formula 12, Formula 13, Formula 14, Formula 15, Formula 16, or Formula 17: [chemical expression included] [chemical expression included] [chemical expression included] or a pharmaceutically acceptable salt thereof. |
| Claim: | 28. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier. |
| Claim: | 29. A pharmaceutical composition comprising at least one compound of claim 25 or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier. |
| Current U.S. Class: | 51425/211 |
| Patent References Cited: | 6124319 September 2000 MacCoss et al. 6525070 February 2003 Rigby et al. 7417045 August 2008 Anilkumar et al. 7566718 July 2009 Wong et al. 2002/0018776 February 2002 Hancock 2003/0055054 March 2003 Medina et al. 2006/0276448 December 2006 Zeng et al. 2006/0276457 December 2006 Yu et al. 2006/0276479 December 2006 Kim et al. 2007/0021611 January 2007 McGuinness et al. 2007/0082913 April 2007 Kim et al. 2008/0039474 February 2008 Rosenblum et al. 2008/0058343 March 2008 Rosenblum et al. 2008/0292589 November 2008 Anilkumar et al. WO93/10091 May 1993 WO93/14077 July 1993 WO99/20606 April 1999 WO00/066558 November 2000 WO02/085861 October 2002 WO03/070242 August 2003 WO03/082335 October 2003 WO03/098185 November 2003 WO03/101970 December 2003 WO2006/088921 August 2006 |
| Other References: | Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001). cited by examiner Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994). cited by examiner Lazzeri and Romagnani, “CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets” Current Drug Targets—Immune, Endocrine & Metabololic Disorders, vol. 5, pp. 109-118 (2005). cited by examiner Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface. cited by examiner Angiolilo, Anne L., et al.; “Human Interferon-inducible Protein 10 is a Potent Inhibitor of Angiogenesis In Vivo”; The Journal of Experimental Medicine; 182:155-162 (1995). cited by other Baggiolini, Marco, et al.; “Interleukin-8 and Related Chemotactic Cytokines—CXC and CC Chemokines”; Advances in Immunol.; 55:97-179 (1994). cited by other Baggiolini, Marco, et al.; “CC chemokines in allergic inflammation”; Immunology Today; 15(3):127-133 (1994). cited by other Clark-Lewis, Ian, et al.; “Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs”; The Journal of Biological Chemistry; 266(34):23128-23134 (1991). cited by other Clark-Lewis, Ian, et al.; “Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg”; Proc. Natl. Acad. Sci. USA; 90:3574-3577 (1993). cited by other Cole, Katherine E., et al.; “Interferon-inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3”; J. Exp. Med.; 187(12):2009-2021 (1998). cited by other Farber, Joshua M.; “A macrophage mRNA selectively induced by γ—interferon encodes a member of the platelet factor 4 family of cytokines”; Proc. Natl. Acad. Sci. USA; 87:5238-5242 (1990). cited by other Farber, Joshua M.; “HuMIG: A New Human Member of the Chemokine Family of Cytokines”; Biochemical and Biophysical Research Communications; 192(1):223-230 (1993). cited by other Galy, Anne H. M., et al.; “IL-1, IL-4, and IFN-γ Differentially Regulate Cytokine Production and Cell Surface Molecule Expression in Cultured Human Thymic Epithelial Cells”; The Journal of Immunology; 147(11):3823-3830 (1991). cited by other Hebert, Caroline A., et al.; “Scanning Mutagenesis of Interleukin-8 Identifies a Cluster of Residues Required for Receptor Binding”; The Journal of Biological Chemistry; 266(28):18989-18994 (1991). cited by other Liao, Fang, et al.; “Human Mig Chemokine: Biochemical and Functional Characterization”; J. Exp. Med.; 182:1301-1314 (1995). cited by other Loetscher, Marcel, et al.; “Chemokine Receptor Specific for IP10 and Mig: Structure, Function, and Expression in Activated T-Lymphocytes”; J. Exp. Med.; 184:963-969 (1996). cited by other Loetscher, Pius, et al.; “Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes”; FASEB J.; 8:1055-1060 (1994). cited by other Luster, Andrew D., et al.; “Ip-10, a -C-X-C- Chemokine, Elicits a Potent Thymus-dependent Antitumor Response In Vivo”; J. Exp. Med.; 178:1057-1065 (1993). cited by other Luster, Andrew D., et al.; “The IP-10 Chemokine Binds to a Specific Cell Surface Heparan Sulfate Site Shared with Platelet Factor 4 and Inhibits Endothelial Cell Proliferation”; J. Exp. Med.; 182:219-231 (1995). cited by other Luster, Andrew D., et al.; “γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins”; Nature; 315:672-676 (1985). cited by other Qin, Shixin, et al.; “The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions”; J. Clin. Invest.; 101(4):746-754 (1998). cited by other Schall, Thomas J., et al.; “Hemokines, leukocyte trafficking, and inflammation”; Current Opinion in Immunology; 6:865-873 (1994). cited by other Seitz, Michael, et al.;. “Enhanced Productionof Neutrophil-activiating Peptide-1/Interleukin-8 in Rheumatoid Arthritis”; Journal Clin. Invest.; 87:463-469 (1991). cited by other Springer, Timothy A.; “Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration”; Annu. Rev. Physio.; 57:827-872 (1995). cited by other Taub, Dennis D., et al.; “Recombinant Human Interferon-inducible Protein 10 is a Chemoattractant for Human Monocytes and T Lymphocytes and Promotes T Cell Adhesion to Endothelial Cells”; The Journal of Experimental Medicine; 177:1809-1814 (1993). cited by other Taub, Dennis D., et al.; “α and β Chemokines Induce NK Cell Migration and Enhance NK-Mediated Cytolysis”; The Journal of Immunol.; 155:3877-3888 (1995). cited by other Uguccioni, Mariagrazia, et al.; “Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1α and MIP-1β on human monocytes”; Eur. J. Immunol.; 25:64-68 (1995). cited by other Qingbei Zeng et al., U.S. Appl. No. 12/519,970; Preliminary Amendment—Filed Jun. 18, 2009. cited by other International Search Report for International Application No. PCT/US2006/005267 dated Jul. 18, 2006. cited by other Notice of Allowance in U.S. Appl. No. 11/545,201 mailed Nov. 17, 2009. cited by other Notice of Allowance in U.S. Appl. No. 11/353,697 mailed Jan. 7, 2010. cited by other Notice of Allowance in U.S. Appl. No. 11/688,014 mailed Jan. 19, 2010. cited by other |
| Primary Examiner: | Wilson, James O |
| Attorney, Agent or Firm: | Meade, Eric A. Banerjee, Krishna G. Kalyanaraman, Palaiyur |
| رقم الانضمام: | edspgr.07868005 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |